ID   HCC827/GR
AC   CVCL_E7R9
RX   PubMed=39080187;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=39080187; DOI=10.1007/s12094-024-03621-2;
RA   Wu S.-J., Liu Y., Wang X., Ren Y.-B., Li X.-H., Wang H.;
RT   "PSIP1 promotes gefitinib resistance in lung adenocarcinoma by
RT   inducing the expression of WASF3 and its downstream ITGB3/AKT
RT   signaling.";
RL   Clin. Transl. Oncol. 27:507-517(2025).
//